Novartis Pipeline

Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development. Please note: the Novartis Pipeline data is updated quarterly.

Download the Novartis Pipeline from the 2023 Annual Report (PDF 0.1 MB)

Show Filters
Showing 109 results
  • IGE025
    Xolair®
    Food Allergy
    Immunology Registration IgE Inhibitor (High-affinity anti-IgE monoclonal antibody)
    Supplementary Indication
  • INC424
    Jakavi®
    Acute GVHD, Pediatrics
    Oncology: Solid Tumors Registration JAK1/2 inhibitor
  • INC424
    Jakavi®
    Chronic GVHD, pediatrics
    Oncology: Solid Tumors Registration JAK1/2 inhibitor
  • INE963
    INE963
    Malaria, uncomplicated
    In-market Brands and Global Health Phase 1
    Lead Indication
  • JDQ443
    JDQ443
    2/3L Non-small cell lung cancer
    Oncology: Solid Tumors Phase 3 KRAS inhibitor
    Lead Indication
  • JDQ443
    JDQ443
    NSCLC and CRC (mono and/or combo)
    Oncology: Solid Tumors Phase 2 ≥ 2027 KRAS inhibitor
    New Indication
  • KAE609
    cipargamin
    Malaria severe
    In-market Brands and Global Health Phase 2 ≥ 2027 PfATP4 inhibitor
    Lead Indication
  • KAE609
    cipargamin
    Malaria, uncomplicated
    In-market Brands and Global Health Phase 2 ≥ 2027 PfATP4 inhibitor
    New Indication
  • KFA115
    KFA115
    Solid tumors
    Oncology: Solid Tumors Phase 1 Novel immunomodulatory agent
    Lead Indication
  • KJX839
    Leqvio®
    Pediatric Hyperlipidemia
    Cardiovascular Phase 3 2025 siRNA (regulation of LDL-C)
    Supplementary Indication
  • KJX839
    Leqvio®
    Secondary prevention of cardiovascular events in patients with elevated levels of LDLC (CVRR-LDLC)
    Cardiovascular Phase 3 ≥ 2027 siRNA (regulation of LDL-C)
    Supplementary Indication
  • KJX839
    Leqvio®
    CVRR (Primary prevention)
    Cardiovascular Phase 3 ≥ 2027 siRNA (regulation of LDL-C)
  • KLU156
    Ganaplacide + lumefantrine
    Malaria, uncomplicated
    In-market Brands and Global Health Phase 3 2026 Non-artemisinin plasmodium falciparum inhibitor
    Lead Indication
  • LEE011
    Kisqali®
    Hormone receptor-positive, HER2-negative breast cancer (HR+, HER2- BC) (adjuvant)
    Oncology: Solid Tumors Registration CDK4/6 inhibitor
    Supplementary Indication
  • LNA043
    LNA043
    Osteoarthritis (combos)
    Immunology Phase 2 ANGPTL3 Agonist
  • LNA043
    LNA043
    Knee osteoarthritis
    Immunology Phase 2 ≥ 2027 ANGPTL3 Agonist
    Lead Indication
  • LNP023
    iptacopan
    C3 glomerulopathy, pediatrics
    Cardiovascular Phase 3 CFB inhibitor (Factor B inhibitor)
  • LNP023
    iptacopan
    IC-MPGN
    Cardiovascular Phase 3 ≥ 2027 CFB inhibitor (Factor B inhibitor)
  • LNP023
    iptacopan
    C3 glomerulopathy (C3G)
    Cardiovascular Phase 3 2024 CFB inhibitor (Factor B inhibitor)
    New Indication
  • LNP023
    iptacopan
    IgA Nephropathy (IgAN)
    Cardiovascular Phase 3 2024 CFB inhibitor (Factor B inhibitor)
    New Indication
Legend

Combination abbreviations:
fulv    fulvestrant
tmx    tamoxifen
gsn    goserelin
NSAI  Non-steroidal aromatase inhibitor
Taf     Tafinlar® (dabrafenib)
Mek   Mekinist® (trametinib)

a    EU filing, approved in US.
b    US filing, approved in EU.
c    US filing, submitted in EU.
d    US pending submission, approved in EU
e    EU filing, submitted in US.

Disclaimer

This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.